Belcesiran

DRUG3 trials

Sponsors

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions

Alpha 1-Antitrypsin Deficiency

Phase 1

Study of DCR-A1AT in Healthy Adult Volunteers

CompletedNCT04174118

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyAlpha 1-Antitrypsin Deficiency

Start: 2019-10-24End: 2023-03-06Updated: 2024-11-06

Phase 2

A Study of Belcesiran in Patients With AATLD

TerminatedNCT04764448

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyAlpha 1-Antitrypsin Deficiency

Start: 2021-02-12End: 2024-05-29Updated: 2026-04-07

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

WithdrawnNCT05146882

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyAlpha 1-Antitrypsin Deficiency

Start: 2021-12-31End: 2022-05-23Updated: 2024-09-19